The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 , ABCG2 , and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms
Abstract
Statins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin‐associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long‐term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP‐C) that facilitates the hepatic uptake of all statins. ABCG2 encodes an efflux transporter (BCRP) that modulates the absorption and disposition of rosuvastatin. CYP2C9 encodes a phase I drug metabolizing enzyme responsible for the oxidation of some statins. Genetic variation in each of these genes alters systemic exposure to statins (i.e., simvastatin, rosuvastatin, pravastatin, pitavastatin, atorvastatin, fluvastatin, lovastatin), which can increase the risk for SAMS. We summarize the literature supporting these associations and provide therapeutic recommendations for statins based on SLCO1B1 , ABCG2 , and CYP2C9 genotype with the goal of improving the overall safety, adherence, and effectiveness of statin therapy. This document replaces the 2012 and 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for SLCO1B1 and simvastatin‐induced myopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Variants in the SLCO1B1 gene, which encodes a transporter protein involved in statin metabolism, have been linked to elevated statin levels in the blood, raising the risk of both DILI and rhabdomyolysis.14”
From Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge (2025) · cites this paper as [14]
In the citing paper
“In addition, polymorphisms in various cytochrome P450 (CYP450) enzymes and specific human leukocyte antigen alleles involved in statin metabolism may contribute to an increased risk of liver injury and rhabdomyolysis.14–16”
From Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875
Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
Serban, M.-C., Colantonio, L. D., Manthripragada, A. D., Monda, K. L., Bittner, V. A., Banach, M., Chen, L., Huang, L., Dent, R., Kent, S. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.036 · Cited by 318
Phenotype standardization for statin-induced myotoxicity
Alfirevic, A., Neely, D., Armitage, J., Chinoy, H., Cooper, R. G., Laaksonen, R., Carr, D. F., Bloch, K. M., Fahy, J., Hanson, A., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.121 · Cited by 220
Self-citationStatin use and musculoskeletal pain among adults with and without arthritis
Buettner, C., Rippberger, M. J., Smith, J. K., Leveille, S. G., Davis, R. B., & Mittleman, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.007 · Cited by 102
Research works printed but not linked: 42
- 10.1038/clpt.2012.57 · DOI · Paper page
- 10.1038/clpt.2014.125 · DOI · Paper page
- 10.1016/j.jacc.2018.11.002 · DOI · Paper page
- 10.1124/pr.110.002857 · DOI
- 10.3390/jcm9010022 · DOI
- Clinical Pharmacogenetics Implementation Consortium (CPIC), CPIC guideline for statins and SLCO1B1, ABCG2 and CYP2C9
- Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB), PGx Gene‐Specific Information Tables
- PharmVar, Pharmacogene Variation Consortium
- 10.1002/cpt.2333 · DOI
- 10.1097/00008571-200204000-00010 · DOI · Paper page
- 10.1002/cpt.1275 · DOI
- 10.1111/cts.12844 · DOI
- 10.1101/gr.129668.111 · DOI
- 10.1182/blood-2012-08-452839 · DOI
- 10.1172/JCI59526 · DOI
- 10.1124/dmd.118.083030 · DOI
- 10.3390/ijms22136678 · DOI
- 10.1002/cpt.1439 · DOI
- 10.1038/ng.1070 · DOI
- 10.1038/clpt.2014.159 · DOI
- 10.1002/cpt.668 · DOI · Paper page
- 10.1002/cpt.2008 · DOI
- 10.1002/cpt.1830 · DOI · Paper page
- Gu Q., 2014, NCHS data brief, no 177
- 10.1038/nrd2423 · DOI · Paper page
- 10.1517/14740338.2011.540568 · DOI
- 10.1038/clpt.2009.79 · DOI · Paper page
- 10.1161/CIRCGENETICS.111.961144 · DOI · Paper page
- 10.1038/nrd1874 · DOI
- 10.1111/cts.12749 · DOI
- 10.1002/cpt.1330 · DOI
- 10.1002/jcph.1080 · DOI
- 10.1016/j.clpt.2005.07.003 · DOI
- 10.1016/j.clpt.2005.06.013 · DOI · Paper page
- 10.1136/hrt.2010.199034 · DOI
- 10.1016/j.jclinepi.2006.11.006 · DOI
- 10.1056/NEJMoa0801936 · DOI · Paper page
- 10.1371/journal.pone.0242422 · DOI
- 10.1016/j.bbrc.2015.09.065 · DOI
- 10.1016/j.cmet.2015.08.002 · DOI
- 10.1001/jamanetworkopen.2020.27092 · DOI
- 10.1161/CIRCGEN.118.002228 · DOI
Cited by
Warden, B. A., Guyton, J. R., Kovacs, A. C., Durham, J. A., Jones, L. K., Dixon, D. L., Jacobson, T. A., & Duell, P. B. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.09.001 · Cited by 111
Türkmen, D., Liang, X., Masoli, J. A. H., Gill, D., Pilling, L. C., & Bowden, J. (2025) · BMC Medicine · doi:10.1186/s12916-025-04228-2 · Cited by 6
Villapalos-García, G., Zubiaur, P., Marián-Revilla, C., Soria-Chacartegui, P., Navares-Gómez, M., Mejía-Abril, G., Rodríguez-Lopez, A., González-Iglesias, E., Martín-Vílchez, S., Román, M., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111566 · Cited by 4
Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge
Singh, H., Khalaf, A., Kunkle, B. F., Gholami, S., Lewis, J. H., & Rangnekar, A. S. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001570 · Cited by 3
Metadata
- Authors
- Cooper‐DeHoff, R. M., Niemi, M., Ramsey, L. B., Luzum, J. A., Tarkiainen, E. K., Straka, R. J., Gong, L., Tuteja, S., Wilke, R. A., Wadelius, M., Larson, E. A., Roden, D. M., Klein, T. E., Yee, S. W., Krauss, R. M., Turner, R. M., Palaniappan, L., Gaedigk, A., Giacomini, K. M., Caudle, K. E., & Voora, D.
- Affiliations
- Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine College of Pharmacy University of Florida Gainesville Florida USA
- Department of Clinical Pharmacology Individualized Drug Therapy Research Program University of Helsinki Helsinki Finland
- Divisions of Clinical Pharmacology & Research in Patient Services Cincinnati Children’s Hospital Medical Center Cincinnati Ohio USA
- Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor Michigan USA
- Department of Experimental and Clinical Pharmacology University of Minnesota College of Pharmacy Minneapolis Minnesota USA
- Department of Biomedical Data Science School of Medicine Stanford University Stanford California USA
- Department of Medicine University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA
- Department of Internal Medicine University of South Dakota Sanford School of Medicine Sioux Falls South Dakota USA
- Department of Medical Sciences Clinical Pharmacogenomics & Science for Life Laboratory Uppsala University Uppsala Sweden
- Division of Cardiovascular Medicine and Division of Clinical Pharmacology Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA
- Department of Bioengineering and Therapeutic Sciences University of California San Francisco San Francisco California USA
- Departments of Pediatrics and Medicine University of California San Francisco California USA
- The Wolfson Centre for Personalised Medicine University of Liverpool Liverpool UK
- Division of Primary Care and Population Health Stanford University School of Medicine Stanford California USA
- Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation Children's Mercy Kansas City and School of Medicine University of Missouri‐Kansas City Kansas City Missouri USA
- Division of Pharmaceutical Sciences Department of Pharmacy and Pharmaceutical Sciences St. Jude Children’s Research Hospital Memphis Tennessee USA
- Department of Medicine Duke Center for Applied Genomics & Precision Medicine Duke University School of Medicine Durham North Carolina USA
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2022-03-11
- Volume
- 111
- Issue
- 5
- Pages
- 1007-1021
- ISSN
- 0009-9236
- 1532-6535
- PMC
- PMC9035072
- Cited by
- 380
- References
- 8
- Language
- en
- Funders
- National Institutes of Health (R24GM115264, U24HG010135)
- H2020 European Research Council (725249)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.